FDA: No Generic for Much-Abused OxyContin
Purdue Pharma News and Media Purdue Pharma L.P. Statement on FDA Approval of New Label for Reformulated OxyContin ® (oxycodone HCL controlled-release) Tablets CII
Get the latest Purdue Pharma news about innovations in prescription and non-prescription products, as well as programs for patients and healthcare professionals.

Reformulated oxycontin

FDA Will Not Approve Generics to Original.

‘Sticky’ OxyContin and OxyNEO formula is.

Oxycodone - Wikipedia, the free.
‘Sticky’ OxyContin and OxyNEO formula is.
FDA Bars Generic Version of OxyContin.

FDA Approves Abuse-Deterrent Labeling for.

The new formulation of OxyContin (aka OxyNEO) will be brought to market that includes Remoxy which will makes the Oxy pill sticky and difficult to crush in order to
Purdue Pharma News: Purdue Innovations.
U.S. health regulators announced on Tuesday that they will not approve any generic versions of the original form of the pain medication OxyContin, which was widely
Date Article; April 17, 2013: Purdue Pharma Statement on FDA Approval of New Label for Reformulated OxyContin and FDA Decision Regarding Withdrawal of Original
The FDA will not approve generic forms of OxyContin that lack abuse-resistant features—and OxyContin’s manufacturer will be able to state that the drug has tamper

The agency approved updated labelling for reformulated OxyContin acknowledging the properties that are expected to reduce abuse of the product. They also confirm that

• OxyContin Sales Data - U.S..

Reformulated oxycontin

Purdue Pharma L.P. Statement on FDA.

Oxycodone is a semi-synthetic opioid synthesized from poppy -derived thebaine. It is a narcotic analgesic generally indicated for relief of moderate to severe pain.